Beam Therapeutics Receives U.S. FDA IND Clearance for BEAM-304, a Base Editing Therapy for Phenylketonuria (PKU)

June 28, 2026

Beam Therapeutics USA

Overview

Beam Therapeutics announced U.S. FDA Investigational New Drug (IND) clearance for BEAM-304, its investigational base editing therapy for Phenylketonuria (PKU). This milestone paves the way for human clinical trials and validates the company’s platform-based strategy to develop multiple mutation-specific editors within a single clinical framework. BEAM-304 represents a potential paradigm shift for PKU patients, offering a one-time treatment targeting the disease’s root cause.

In Depth

Key Findings

Beam Therapeutics has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for BEAM-304, its novel base editing therapy candidate for the treatment of Phenylketonuria (PKU). This approval marks a crucial step, allowing Beam Therapeutics to initiate human clinical trials for BEAM-304.

Technical / Clinical Details

BEAM-304 is designed to correct specific mutations in the phenylalanine hydroxylase (PAH) gene using advanced base editing technology, thereby restoring functional PAH enzyme activity which is deficient in PKU patients. Unlike conventional enzyme replacement or dietary management, BEAM-304 aims to address the root genetic cause of the disease, potentially offering a one-time curative treatment. Beam Therapeutics has adopted a platform-based strategy for this program, enabling the development of multiple mutation-specific editors within a unified clinical framework, which is critical for addressing the diverse genetic landscape of PKU patients.

Background & Context

Phenylketonuria (PKU) is a rare inherited metabolic disorder caused by mutations in the PAH gene, leading to severe neurological damage if untreated early. Current treatments primarily involve strict dietary restrictions and enzyme supplementation, significantly impacting patient quality of life. Base editing, a refined gene-editing technique, offers more precise single-base corrections without inducing double-strand DNA breaks, a common concern with CRISPR-Cas9, thus potentially reducing off-target effects. This precision makes base editing highly attractive for developing safer and more effective treatments for genetic diseases.

Strategic Significance & Outlook

The FDA’s IND clearance underscores the robustness of Beam Therapeutics’ base editing platform and the significant potential of BEAM-304 to provide a novel therapeutic option for PKU patients. Future clinical trial data will be instrumental in establishing the safety and efficacy of BEAM-304, which, if successful, could fundamentally alter the PKU treatment paradigm. This regulatory advancement is also expected to catalyze the development of other base editing therapies for a broader range of genetic disorders, reinforcing Beam’s leadership in this innovative space.

Source: https://investors.beamtx.com/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.